Bio-Techne Corporation

Bio-Techne is the life-sciences reagents/instruments franchise (Protein Sciences + Diagnostics and Spatial Biology) — now under a June 25 all-cash merger agreement with Merck KGaA at $73.00 per share. The stock is up 37% over 12 months at 99.5% of the 52-week range as the merger-arb spread compresses toward the deal price.

• The merger event is the whole trade: Bio-Techne entered an Agreement and Plan of Merger with Merck KGaA (Germany) on June 25 — each share of TECH common stock converts to $73.00 cash at closing, unanimous board approval, plus the June 25 joint press release confirmed execution. That's a specific take-private with a ~1% arb spread remaining ($72.23 vs $73.00 target).

• The operating results are steady: Q4 FY26 EPS $0.52 vs $0.52 estimate (in-line), Q3 EPS $0.33, Q1 FY26 EPS $0.25 — a specific pattern of small beats and in-lines. Analysts model FY27 EPS $2.05 rising to $2.32 FY28 (which becomes moot at close, but reflects the underlying operating trajectory).

• The counterweights are honest: 100x TTM P/E is very demanding (bookkeeping distortion from small trailing base), 43x EV/EBITDA priced for continued execution, specific insider selling into the merger price on July 23-29 (Hippel $5.9M M-Exempt + $3.7M F-InKind; Kelderman $3.3M + $2.1M) is standard pre-merger tax-planning behavior — the tape is behaving like a normal near-arb-close situation, and the ~1% remaining spread reflects standard closing-timeline risk plus small regulatory-approval overhang.

The next event is the merger close — a specific closing-date announcement, an antitrust-approval confirmation from EU/US regulators, and specific commentary on the closing timeline is what compresses the spread to zero at $73. A specific antitrust-approval delay, a Merck KGaA financing issue, or a fresh material-adverse-change dispute is what would take a name at 99.5% of 52w range back below $68 (typical break-up scenario).